for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneus Ltd

RGS.AX

Latest Trade

0.08AUD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.06

 - 

0.20

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Latest Developments

Regeneus Ltd Announces Institutional Placement To Raise Up To $4.5 Mln

May 7 (Reuters) - Regeneus Ltd <RGS.AX>::REGENEUS ANNOUNCES INSTITUTIONAL PLACEMENT-RGS.AX.UP TO $4.5 MILLION SECURED IN PLACEMENT TO NEW LIFE SCIENCES CAPITAL LLC.PURCHASE PRICE OF PLACEMENT WILL INITIALLY BE $0.20/SHARE.

Regeneus Granted New Patent To Target Pain In Japan

Feb 9 (Reuters) - Regeneus Ltd <RGS.AX>::REGENEUS TO BE GRANTED NEW PATENT TO TARGET PAIN IN JAPAN.JAPANESE PATENT OFFICE DECIDED TO GRANT CO NEW KEY PATENT COVERING USE OF ITS LEAD STEM CELL TECHNOLOGY PROGENZA.

Regeneus Says Co & Kyocera Sign Progenza OA Licence And Collaboration Agreement

Aug 11 (Reuters) - Kyocera Corp <6971.T>::REGENEUS & KYOCERA SIGN PROGENZA OA LICENCE AND COLLABORATION AGREEMENT.AGREEMENT TO DEVELOP & COMMERCIALISE PROGENZA FOR KNEE OSTEOARTHRITIS IN JAPAN.CO TO GET US$19M IN UPFRONT, DEVELOPMENT & REGULATORY MILESTONE PAYMENTS.

Regeneus Says Kyocera Completed Due Diligence On Progenza

May 18 (Reuters) - Regeneus: :KYOCERA CORP COMPLETED DUE DILIGENCE PROCESS ON ITS LEAD STEM CELL PLATFORM TECHNOLOGY PROGENZA FOR KNEE OSTEOARTHRITIS TREATMENT.PROGENZA OA HAS MET KYOCERA'S DUE DILIGENCE CRITERIA.

Regeneus Signs MoU Agreement With Kyocera On Exclusive Negotiation Rights For Progenza In Japan

March 2 (Reuters) - Regeneus Ltd <RGS.AX>::SIGNS MOU AGREEMENT WITH KYOCERA ON EXCLUSIVE NEGOTIATION RIGHTS FOR PROGENZA IN JAPAN.UNDER MOU, UPFRONT PAYMENT OF A$1.4 MILLION.

Regeneus Says HY Total Comprehensive Loss $1.2 Mln

Feb 28 (Reuters) - Regeneus Ltd <RGS.AX>::HY TOTAL COMPREHENSIVE LOSS $1.2 MILLION VERSUS LOSS OF $2.7 MILLION.

Regeneus Ltd Mutually Agreed With AGC Inc To Terminate Manufacturing Licence And JV Agreement

Dec 20 (Reuters) - Regeneus Ltd <RGS.AX>::MUTUALLY AGREED WITH JAPAN-BASED MANUFACTURER AGC INC TO TERMINATE THEIR EXCLUSIVE MANUFACTURING LICENCE AND JOINT VENTURE AGREEMENT.AGC ELECTED TO CONVERT $2.5 MILLION OF UPFRONT, MILESTONE PAYMENTS INTO EQUITY OWNERSHIP IN CO OF ORDINARY SHARES AT A$0.16 PER SHARE.

Regeneus Announces Positive Preclinical Trial Results For Progenza

July 23 (Reuters) - Regeneus Ltd <RGS.AX>::ANNOUNCES POSITIVE PRECLINICAL TRIAL RESULTS FOR PROGENZA IN TREATING NEUROPATHIC PAIN.

Regeneus Appointed Leo Lee As CEO

Jan 23 (Reuters) - Regeneus Ltd <RGS.AX>::APPOINTED LEO LEE AS CEO.LEO WILL SUCCEED OUTGOING CEO, JOHN MARTIN.

Regeneus Says Chinese Patent Granted For Biomarkers To Monitor Disease Progression For Stem Cell Therapy

Dec 3 (Reuters) - Regeneus Ltd <RGS.AX>::CHINESE PATENT GRANTED FOR BIOMARKERS TO MONITOR DISEASE PROGRESSION FOR STEM CELL THERAPY.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up